K182692

Substantially Equivalent

BD MAX CTGCTV2, BD MAX System

Applicant: Becton, Dickinson and Company
Product code: OUY
Advisory panel: Immunology
Date received: 2018-09-27
Decision date: 2019-01-08
Decision: Substantially Equivalent
Clearance type: Traditional
Location: Sparks, MD, US

Download summary PDF View on FDA.gov ↗

Data sourced from openFDA. This site is unofficial and independent of the FDA.